4-[2-(4-Aminopiperidin-1-yl)ethyl]-6-chloro-2H-1,4-benzoxazin-3(4H)-one | 917341-97-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 4-[2-(4-Aminopiperidin-1-yl)ethyl]-6-chloro-2H-1,4-benzoxazin-3(4H)-one
• 英文别名: 4-[2-(4-aminopiperidin-1-yl)ethyl]-6-chloro-1,4-benzoxazin-3-one
• CAS: 917341-97-0
• 化学式: C₁₅H₂₀ClN₃O₂
• 分子量: 309.796
• InChiKey: VCIBIJLBDGUJSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  58.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-氧代-3,4-二氢-2H-吡啶并[3,2-b][1,4]噁嗪-6-甲醛 、 4-[2-(4-Aminopiperidin-1-yl)ethyl]-6-chloro-2H-1,4-benzoxazin-3(4H)-one 在 sodium cyanoborohydride 作用下， 以 甲醇 、 1,2-二氯乙烷 为溶剂， 生成 6-[((1-[2-(6-chloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethyl]piperidin-4-yl)amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
  参考文献：
  名称：

  Exploring Left-Hand-Side substitutions in the benzoxazinone series of 4-amino-piperidine bacterial type IIa topoisomerase inhibitors

  摘要：

  An SAR survey at the C-6 benzoxazinone position of a novel scaffold which inhibits bacterial type IIa topoisomerase demonstrates that a range of small electron donating groups (EDG) and electron withdrawing groups (EWG) are tolerated for antibacterial activity. Cyano was identified as a preferred substituent that affords good antibacterial potency while minimizing hERG cardiac channel activity. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.126
• 作为产物：
  描述：

  6-氯-2H-1,4-苯并噁嗪-3(4H)-酮 在 sodium hydride 、 三氟乙酸 作用下， 以 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-[2-(4-Aminopiperidin-1-yl)ethyl]-6-chloro-2H-1,4-benzoxazin-3(4H)-one
  参考文献：
  名称：

  Exploring Left-Hand-Side substitutions in the benzoxazinone series of 4-amino-piperidine bacterial type IIa topoisomerase inhibitors

  摘要：

  An SAR survey at the C-6 benzoxazinone position of a novel scaffold which inhibits bacterial type IIa topoisomerase demonstrates that a range of small electron donating groups (EDG) and electron withdrawing groups (EWG) are tolerated for antibacterial activity. Cyano was identified as a preferred substituent that affords good antibacterial potency while minimizing hERG cardiac channel activity. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.126

文献信息

• Compounds for the treatment of multi-drug resistant bacterial infections
  申请人：AstraZeneca AB

  公开号：US07875715B2

  公开（公告）日：2011-01-25

  The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

  本发明涉及表现出抗菌活性的化合物，其制备过程，含有其作为活性成分的药物组合物，以及它们作为药物的使用和用于制造用于治疗温血动物（如人类）细菌感染的药物的使用。特别地，本发明涉及用于治疗温血动物（如人类）细菌感染的有用化合物，更具体地涉及这些化合物用于制造用于治疗温血动物（如人类）细菌感染的药物。
• COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS
  申请人：Breault Gloria

  公开号：US20110092495A1

  公开（公告）日：2011-04-21

  The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

  本发明涉及表现出抗菌活性的化合物，其制备过程，含有它们作为活性成分的制药组合物，它们作为药物的使用以及它们在制造用于治疗温血动物（如人类）细菌感染的药物中的使用。特别是本发明涉及用于治疗温血动物（如人类）细菌感染的有用化合物，更具体地涉及这些化合物在制造用于治疗温血动物（如人类）细菌感染的药物中的使用。
• US7875715B2
  申请人：——

  公开号：US7875715B2

  公开（公告）日：2011-01-25
• US8124602B2
  申请人：——

  公开号：US8124602B2

  公开（公告）日：2012-02-28
• [EN] COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS<br/>[FR] COMPOSES POUR LE TRAITEMENT D'INFECTIONS BACTERIENNES MULTIRESISTANTES AUX ANTIBIOTIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2006134378A1

  公开（公告）日：2006-12-21

  [EN] The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.
  [FR] L'objet de cette invention concerne des composés ayant démontré une activité antibactérienne, leurs procédés de préparation, les compositions pharmaceutiques les contenant comme principe actif, leur utilisation comme médicament et dans la préparation pour le traitement d'infections bactériennes chez les animaux à sang chaud, notamment les êtres humains. L'invention concerne, plus particulièrement, des composés pour le traitement d'infections bactériennes chez les animaux à sang chaud, notamment les êtres humains, plus précisément l'utilisation de ces composés dans la préparation de médicaments pour le traitement d'infections bactériennes chez les animaux à sang chaud, notamment les êtres humains.